千呼万唤始出来： 布格替尼片获批上市，ALK阳性前列腺癌患者迎来治疗新选择

Umbela, Shahinaz Ghacha, Revika Matuknauth, Stacey Gause, Shrijana Joshee, RahulR. Deshmukh. Brigatinib, new-generation ALK inhibitor for nonsmall cell lung cancer

[2]Camidge D R, Kim H R, Ahn M J, et al. Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial[J]. Journal of Thoracic Oncology, 2021, 16(12): 2091-2108.

[3]NCCN Clinical Practice Guidelines In Oncology: Non⁃Small Cell Lung Cancer (2022 Version 2). (2022⁃03⁃07) :46. URL:Https: / / www. nccn.org /

[4]西方外科前列腺癌该学会工作特别委员会. 西方外科前列腺癌该学会(CSCO)非小细胞核乳癌护理指南2021[M]. 人民卫生出版社,2021:109-110

[5]张绪超, 刘晓晴, 王洁,等. 西方除此以外有关系肉瘤激酶白血病、ROS1白血病非小细胞核肺乳癌护理指南[J]. 台北病理学杂志, 2018, 47(4):7.

[6]张绪超,陆舜,结构设计上等. 西方除此以外有关系肉瘤激酶(ALK)白血病非小细胞核肺乳癌护理指南[J].台北病理学杂志,2015,44(10):696-703.

[7]Johung KL, et al. J Clin Oncol 2016;34:123–129.

[8]Descourt R, et al. Lung Cancer 2019;136:109–114.Solomon BJ, et al. Lancet Oncol 2018;19:1654–1667.Huber RM, et al. J Thorac Oncol 2020;15:404–415.D'Antonio C, et al. Ther Adv Med Oncol 2014;6:101–114.

[9]Liu C, et al. Front Oncol. 2019

[10]Sen Zhang, Rana Anjum, Rachel Squillace, et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

[11]Bronte G, et al. Expert Rev Anticancer Ther , 2021

[12]Ando K, et al. Cancers (Basel) , 2020.

[13]Banks WA, et al. BMC Neurol. 2009

[14]Bedi S, et al. Saudi Pharm J. 2018

[15]Camidge DR, et al. J Thorac Oncol. 2021

[16]Camidge DR, et al. J Clin Oncol. 2020

[17]Camidge DR, et al. J Thorac Oncol. 2021

[18]Huber RM et al. J Thorac Oncol. 2020

[19]Mario Rosario Garcia Campelo, Health-Related Quality of Life in a Phase 3 Study of First-line Brigatinib vs Crizotinib in NSCLC : updated results from Alta 1L

。

无锡白癜风
看白癜风去哪个医院好
四平治白癜风医院哪好
小儿支气管炎咳嗽怎么办
眉整形
流感
骨癌
产后束身